RxDoctor Payments Data

Amanda Johnson

Pediatrics · Harriman, TNNPI 1508374174

Payments from drug & device makers

$3,539in general payments, 2019–2025

Across 163 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$695
  • GSK$649
  • Sanofi$449
  • AstraZeneca$441
  • Takeda Pharmaceuticals U.S.A., Inc.$299
  • Sanofi-aventis U.S. LLC$199
  • plus $808 from 12 others

What the payments were for

  • Food & beverage$3,29493%
  • Education$2467%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,539 in reported general payments places this provider in the 95th percentile of 1,338 pediatrics providers in Tennessee.

See all pediatrics providers in Tennessee

Medicare billing

Part B allowed, 2024
$326,428
Medicare patients
432
Services billed
11,499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab32$114,824
Dupixent SyringeDupilumab14$50,516
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$19,676
Spiriva RespimatTiotropium Bromide23$15,460
Breo ElliptaFluticasone/Vilanterol22$9,281
Azelastine Hcl146$4,786
Epinephrine23$4,480
SymbicortBudesonide/Formoterol Fumarate11$3,000
Fluticasone Propionate190$2,960
Ipratropium Bromide51$2,159
Montelukast Sodium194$1,866
Albuterol Sulfate HfaAlbuterol Sulfate49$1,296
Hydroxyzine Hcl28$321
Pantoprazole Sodium18$137
Famotidine12$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$649$28,95755 claims
Boehringer IngelheimSpiriva Respimat$24$15,46023 claims
AstraZenecaSymbicort$441$3,00011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,338 pediatrics providers in Tennessee.

Other pediatrics in Harriman

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →